ArticleBMC infectious diseases2025
Negligible clinical impact of subsequent non-tuberculous mycobacteria isolation during MDR/RR-TB treatment: a 9-year retrospective cohort study from Wenzhou, China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic Discordance During MDR-TB Treatment: Retrospective Identification ofMicroorganisms · 2026Article
- Prevalence of nontuberculous mycobacteria isolates and pulmonary disease from respiratory tract samples in persons investigated for presumed tuberculosis from three West African countries, an analysis of three prospective cohort studies.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe frequency of clinical isolation of non-tuberculous mycobacteria (NTM) in patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB) is increasing, but its relevance remains unclear. This study aimed to assess the frequency of NTM isolation and its clinical relevance in respiratory specimens from MDR/RR-TB patients in Wenzhou, China.
methodsMedical records of MDR/RR-TB patients with NTM isolated from 2014 to 2022 were reviewed retrospectively. To establish the clinical relevance, the diagnostic criteria for nontuberculous mycobacterial pulmonary disease (NTM-PD) published by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) were applied.
resultsBetween 2014 and 2022, a total of 922 patients were enrolled, among whom 45 (4.9%) cases yielded NTM isolates, resulting in the isolation of 68 distinct NTM strains. The most prevalent NTM species was M. abscessus, accounting for 36.8% (25/68) of the isolates, followed by M. intracellulare at 22.1% (15/68) and M. avium at 8.8% (6/68). Notably, only five cases (0.54%) met the microbiologic criteria specified in the ATS/IDSA guidelines. Four of these cases received no specific NTM treatment and achieved a favorable prognosis with anti-TB therapy. Remarkably, a single case out of 922 (0.11%) was identified as having concomitant MDR/RR-TB and NTM-PD.
conclusionsThe clinical relevance of respiratory NTM isolates in patients with MDR/RR-TB is generally low, with the overwhelming majority of these NTM isolates being either colonizers or contaminants. Consequently, in most cases, those with concomitant NTM isolates do not require specific therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.